ERK
ERK is a key protein in the MAPK (Mitogen-Activated Protein Kinase) signaling pathway, which is involved in transmitting signals from cell surface receptors to the DNA in the cell nucleus. ERK plays a crucial role in the regulation of various cellular processes, including proliferation, differentiation, and survival. Dysregulation of ERK signaling is associated with the development of cancer and other diseases, making it an important target for therapeutic intervention. At CymitQuimica, we offer a selection of high-quality ERK inhibitors and modulators to support your research in cell signaling, oncology, and therapeutic development.
Found 193 products of "ERK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
NMDAR/TRPM4-IN-2
CAS:<p>Potent NMDAR/TRPM4-IN-2 blocks NMDAR/TRPM4, protects brain and retinal neurons, and prevents mitochondrial dysfunction with an IC50 of 2.1 μM.</p>Formula:C11H19BrCl2N2Purity:98.77%Color and Shape:SolidMolecular weight:330.092(E)-GABAB receptor antagonist 1
CAS:<p>(E)-GABAB antagonist 1 inhibits GABA IP3 production, with an IC50 of 37.9 μM and acts as a selective negative modulator.</p>Formula:C18H24O4Purity:98.09%Color and Shape:SolidMolecular weight:304.38ZINC12409120
CAS:<p>ZINC12409120 (R-4584) is a selective ERK inhibitor.ZINC12409120 inhibits ERK with an IC50 of 5.0 μM.ZINC12409120 inhibits ERK activity by interfering with FGF23</p>Formula:C20H16N4O2Purity:99.71% - 99.95%Color and Shape:SolidMolecular weight:344.37RLX-33
CAS:<p>RLX-33 blocks RXFP3 and relaxin 3 effects, controls food intake in rats, and may help study metabolic syndrome.</p>Formula:C24H19ClN4O4Purity:99.89%Color and Shape:SolidMolecular weight:462.89I-287
CAS:<p>I-287 is a selective, orally active PAR2 inhibitor that functions as a negative allosteric modulator of Gαq and Gα12/13 activity and their downstream effectors.</p>Formula:C30H30ClFN4O4Color and Shape:SolidMolecular weight:565.04ERK1/2 inhibitor 9
CAS:<p>ERK1/2 Inhibitor 9 (Probe 1), a covalent antagonist of ERK1/2, exhibits sub-micromolar efficacy in cellular assays (A375 GI50=0.47 μM) and facilitates the</p>Formula:C31H32ClN7O3Purity:98%Color and Shape:SolidMolecular weight:586.08ERK Inhibitor II (Negative control)
CAS:<p>ERK Inhibitor II, a control, blocks ERK and insulin receptor activation, aiding diabetes research.</p>Formula:C18H12N6OColor and Shape:SolidMolecular weight:328.33MRS2693 trisodium
CAS:<p>MRS2693 trisodium, a selective P2Y6 agonist with an EC50 of 0.015 μM, demonstrates cytoprotective effects in a mouse hindlimb skeletal muscle ischemia-reperfusion injury model by reducing NF-kappaB activation and stimulating the ERK1/2 pathway [1] [2].</p>Formula:C9H10IN2Na3O12P2Color and Shape:SolidMolecular weight:596ERK1/2 inhibitor 8
CAS:<p>ERK1/2 inhibitor 8 is a potent inhibitor of ERK that acts on ERK2 (IC50: 0.48 nM).</p>Formula:C23H20ClN7O2SColor and Shape:SolidMolecular weight:493.97MEK-IN-6
CAS:<p>MEK-IN-6 (Example 69), a potent MEK inhibitor, effectively inhibits ERK1/2 (Thr202/Tyr204) phosphorylation in A375 cells, with an IC50 of 2 nM, making it</p>Formula:C18H20FN3O4SPurity:98%Color and Shape:SolidMolecular weight:393.43KRAS G12C inhibitor 61
CAS:<p>KRAS G12C inhibitor 61 (Example 3) demonstrates potent activity by inhibiting phospho-ERK 1/2 in MIA PaCa-2 cells, reflected in an IC50 value of 9 nM.</p>Formula:C31H33ClFN7O2Purity:98%Color and Shape:SolidMolecular weight:590.09K145 hydrochloride
CAS:<p>K145 hydrochloride is a selective sphk2 inhibitor with substrate competitiveness and oral activity, with IC50 of 4.3 µM and Ki of 6.4 µM.</p>Formula:C18H25ClN2O3SPurity:99.8%Color and Shape:SolidMolecular weight:384.92(R)-VX-11e
CAS:<p>(R)-VX-11e is an isomer of VX-11e, a potent and selective ERK2 inhibitor with potential to inhibit tumor growth.</p>Formula:C24H20Cl2FN5O2Purity:98.73%Color and Shape:SolidMolecular weight:500.35DL-threo dihydrosphingosine
CAS:<p>DL-threo dihydrosphingosine blocks ERK, inhibits smooth muscle proliferation, and works against growth factor/G-protein ERK activation.</p>Formula:C18H39NO2Color and Shape:SolidMolecular weight:301.51Inflachromene
CAS:<p>Inflachromene (ICM) is an inhibitor of HMGB1 and HMGB expression with anti-inflammatory activity.Inflachromene is used in the study of epilepsy.</p>Formula:C21H19N3O4Purity:97.36% - 99.88%Color and Shape:SolidMolecular weight:377.39CXJ-2
CAS:<p>CXJ-2, a cyclic peptide, binds EDPs, inhibits PI3K/ERK, and reduces hepatic cell growth/migration, offering antifibrotic effects.</p>Formula:C55H87N15O22Purity:98%Color and Shape:SolidMolecular weight:1310.37ERK1/2 inhibitor 5
CAS:<p>ERK1/2 inhibitor 5: potent against ERK1/2, may combat cancer and inflammation.</p>Formula:C28H32ClFN6O5Color and Shape:SolidMolecular weight:587.04ERK1/2 inhibitor 7
CAS:<p>ERK1/2 inhibitor 7 is a potent inhibitor of ERK, acting on ERK2 (IC50: 0.94 nM).</p>Formula:C23H22FN7OSColor and Shape:SolidMolecular weight:463.53EVT801
CAS:<p>EVT801 is a highly selective and low-toxic VEGFR-3 inhibitor that inhibits VEGF-C-induced tumor lymphoid and angiogenesis and reduces CCL4, CCL5 and MDSC.</p>Formula:C19H21N5O3Purity:97.4%Color and Shape:SolidMolecular weight:367.4ERK-IN-2 free base
CAS:<p>ERK-IN-2 free base inhibits ERK2 (IC50: 1.8 nM); potential off-target effects at >10 μM.</p>Formula:C16H17N5O2Color and Shape:SolidMolecular weight:311.34Laxiflorin B
CAS:<p>Laxiflorin B, a novel selective inhibitor of ERK 1/2 derived from herbal sources, exhibits antitumor activity [1].</p>Formula:C20H24O5Purity:98%Color and Shape:SolidMolecular weight:344.4JWG-071
CAS:<p>JWG-071: First ERK5 kinase probe, BET inhibitor, 1 μM BRD4 IC, boosts ERK5 function and BRD4 selectivity.</p>Formula:C34H44N8O3Purity:98.33%Color and Shape:SolidMolecular weight:612.77MK-8353
CAS:<p>MK-8353 (SCH900353) is a potent, selective and orally available inhibitor of ERK1/2 (IC50s of 23.0 nM and 8.8 nM, respectively)</p>Formula:C37H41N9O3SPurity:96.15% - 97.19%Color and Shape:SolidMolecular weight:691.84ERK1/2 inhibitor 6
CAS:<p>ERK1/2 inhibitor 6 - potent cancer/inflammation treatment from WO2021063335A1.</p>Formula:C27H29ClFN7O5Color and Shape:SolidMolecular weight:586.01DOR agonist 2
CAS:<p>Compound 3 (DOR agonist 2) acts as a Delta Opioid Receptor agonist. It inhibits the expression of TNF-α, obstructs NF-κB transportation to the nucleus, and activates the G protein-mediated ERK1/2 pathway. This compound is useful for research into neurodegenerative diseases.</p>Formula:C29H26N2O3Color and Shape:SolidMolecular weight:450.53ERK2 IN-1
CAS:<p>ERK2 IN-1 is a selective ERK2 inhibitor with an IC50 of 7 nM.</p>Formula:C36H34FN7O2SPurity:98%Color and Shape:SolidMolecular weight:647.76ATX inhibitor 26
CAS:<p>ATX inhibitor 26 is an Autotaxin (ATX) inhibitor with an IC50 of 57 nM in human plasma. It effectively inhibits cell migration and collagen gel contraction. Additionally, ATX inhibitor 26 demonstrates significant antifibrotic activity, reducing collagen deposition in a Bleomycin (BLM)-induced pulmonary fibrosis model.</p>Formula:C18H19Cl2N7O3Color and Shape:SolidMolecular weight:452.30AL 8810
CAS:<p>AL-8810 is an 11β-fluoro analog of PGF 2α with selective antagonist effects at the PGF 2α receptor (FP receptor) [1].</p>Formula:C24H31FO4Color and Shape:SolidMolecular weight:402.5SOS1 activator 2
CAS:<p>SOS1 activator 2 (Compound 65) is a benzothiazole derivative and an activator of SOS1. It demonstrates a high binding affinity for SOS1, with a Kd of 9 nM. By modulating the Ras-ERK signaling pathway, SOS1 activator 2 is suitable for tumor research.</p>Formula:C26H28ClFN6Color and Shape:SolidMolecular weight:478.992KRASG12C IN-15
CAS:<p>KRASG12C IN-15 (Compound 21) is an orally active KRASG12C inhibitor that effectively blocks SOS1-mediated GDP/GTP exchange with an IC50 of 19 nM. It inhibits ERK phosphorylation with an IC50 of 0.051 μM and reduces the viability of KRASG12C mutant MIA PaCa-2 cells with an IC50 of 0.023 μM. Additionally, KRASG12C IN-15 demonstrates antitumor activity in a MIA PaCa-2 xenograft mouse model.</p>Formula:C31H32FN3O2Color and Shape:SolidMolecular weight:497.603KRAS inhibitor-27
CAS:<p>KRAS inhibitor-27 (Compound 15h) is a KRAS inhibitor that effectively targets KRAS G12D/G12V mutated cells (AsPC-1 and SW620) and wild-type KRAS cells (HT-29), with IC50 values of 378 nM, 0.6 nM, and 3230 nM, respectively. It reduces ERK phosphorylation, with IC50 values of 0.6 nM and 1 nM in AsPC-1 and SW620 cells, respectively, and decreases DUSP4 expression, thereby inhibiting the MAPK signaling pathway.</p>Formula:C31H28ClF3N6O3SColor and Shape:SolidMolecular weight:657.106Coelogin
CAS:<p>Coelogin is an orally effective bone-protective agent that activates ER-Erk and Akt-dependent signaling pathways, thereby stimulating osteoblast differentiation. It is utilized in osteoporosis research.</p>Formula:C17H16O5Color and Shape:SolidMolecular weight:300.31MAP855
CAS:<p>MAP855: potent, selective, oral MEK1/2 inhibitor; IC50=3 nM, pERKEC50=5 nM; effective on wild-type/mutant MEK1/2.</p>Formula:C28H23ClF2N6O3Color and Shape:SolidMolecular weight:564.97Hypothemycin
CAS:<p>Hypothemycin, a fungal polyketide, inhibits multiple kinases (VEGFR, MEK, FLT-3, PDGFR, ERK) with Kis ranging from 10 nM to 2.4 μM.</p>Formula:C19H22O8Purity:98%Color and Shape:SolidMolecular weight:378.37KU004
CAS:<p>KU004, a potent dual EGFR/HER2 inhibitor, exhibits anticancer properties. It inhibits the proliferation of human breast cancer SKBR3 cells by inducing G1 phase arrest. KU004 blocks the activation of HER2, EGFR, and the downstream Akt and Erk pathways, primarily inducing apoptosis (Apoptosis) through the extrinsic pathway. Additionally, KU004 is a novel quinazoline derivative.</p>Formula:C29H27ClFN4O2PColor and Shape:SolidMolecular weight:548.98SHR2415
<p>SHR2415: Potent, selective ERK1/2 inhibitor, oral; ERK1 IC50: 2.8 nM, ERK2 IC50: 5.9 nM; effective in Colo205 (IC50: 44.6 nM), for cancer research.</p>Formula:C23H22ClN7O2Color and Shape:SolidMolecular weight:463.92(rel)-AR234960
CAS:<p>(rel)-AR234960 is an active relative configuration of AR234960. AR234960 is a non-peptide agonist of MAS.</p>Formula:C27H30FN5O5SColor and Shape:SolidMolecular weight:555.63ERK-IN-2
CAS:<p>ERK-IN-2, an ERK2 inhibitor, exhibits an IC50 value of 1.8 nM. At doses greater than 10 μM, it may induce off-target toxicity and/or activity [1].</p>Formula:C16H18ClN5O2Purity:98%Color and Shape:SolidMolecular weight:347.80Rineterkib
CAS:<p>Rineterkib (ERK-IN-1) is an inhibitor of RAF and ERK1/2 activating mutations in the MAPK pathway.</p>Formula:C26H27BrF3N5O2Purity:99.73%Color and Shape:SolidMolecular weight:578.42Omtriptolide
CAS:<p>Omtriptolide, triptolide purified from the Chinese herb, is a water-soluble derivative prodrug.</p>Formula:C24H28O9Purity:98%Color and Shape:SolidMolecular weight:460.479Ravoxertinib hydrochloride
CAS:<p>Ravoxertinib hydrochloride is an orally bioavailable and selective inhibitor for ERK kinase activity (IC50: 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively).</p>Formula:C21H19Cl2FN6O2Purity:98%Color and Shape:SolidMolecular weight:477.32Pamoic acid
CAS:<p>Pamoic acid is the orphan G protein-coupled receptor GPR35 agonist. Pamoic acid activates ERK and beta-arrestin2 and causes antinociceptive activity.</p>Formula:C23H16O6Purity:99.99%Color and Shape:Fine Yellow PowderMolecular weight:388.37WQ-C-401
CAS:<p>WQ-C-401 is an orally active inhibitor of the platelet-derived growth factor receptor (PDGFR). It inhibits cell proliferation by blocking PDGFR auto-phosphorylation in a concentration-dependent manner, with EC50 values of 3.5 nM for PDGFRαY849 and 5.8 nM for PDGFRβY1021. Additionally, WQ-C-401 suppresses the proliferation and migration of PASMCs by inhibiting PDGF-BB-induced phosphorylation of ERK1/2, reduces collagen I synthesis, and increases α-SMA expression, thereby preventing pulmonary vascular remodeling. This compound shows promise for research in the field of pulmonary arterial hypertension.</p>Formula:C24H26N4O3Color and Shape:SolidMolecular weight:418.49Ref: TM-T200766
Discontinued product
